Organon

Genentech filed the first BPCIA litigation against Shanghai Henlius Biotech and Organon on August 14, 2025, alleging infringement of 24 patents by their proposed pertuzumab biosimilar HLX11.

Daré Bioscience announced positive interim safety and efficacy results from its Phase 3 trial of Ovaprene, an investigational monthly hormone-free intravaginal contraceptive.

The NHS in England has approved relugolix combination therapy as the first long-term daily oral treatment for endometriosis, expected to benefit around 1,000 women annually whose symptoms persist despite previous treatments.

Daré Bioscience received a $6 million non-dilutive grant installment, bringing total funding to $37.8 million of up to $49 million committed for DARE-LARC1 contraceptive development.

Organon's investigational endometriosis drug OG-6219 failed to meet its primary efficacy endpoint in the Phase II ELENA proof-of-concept study, showing no improvement in moderate-to-severe pelvic pain compared to placebo.

Amgen filed three separate BPCIA patent infringement lawsuits in late June 2025 against companies developing denosumab biosimilars, including Hikma/Gedeon Richter, Shanghai Henlius/Organon, and Biocon.

CT-P47, a tocilizumab biosimilar, showed comparable efficacy and safety to reference Actemra over 52 weeks in a phase 3 trial involving 444 rheumatoid arthritis patients.

The European Medicines Agency has confirmed suicidal thoughts as a rare side effect of finasteride, a medication commonly used to treat male pattern hair loss in men aged 18-41.

Conduit Pharmaceuticals has filed groundbreaking patents for a dual active cocrystal formulation of tapinarof (VTAMA®), potentially addressing both inflammatory conditions and associated symptoms like pain and itch.

Daré Bioscience has unveiled a dual-path approach to make its proprietary Sildenafil Cream formulation available via prescription by Q4 2025, responding to healthcare community urging and women's demand.